News
Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...
US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...
The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...
Zacks Investment Research on MSN3h
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
MarketBeat on MSN4h
Are Growth Stocks Back? 3 That Look Like Winners to Buy NowIn today's dynamic and volatile market terrain, investors are increasingly drawn to opportunities that promise robust growth ...
Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of ...
In a move that raises questions about its future role and composition, HHS Secretary Robert F. Kennedy Jr.'s office has called off a scheduled meeting of the U.S. Preventive Services Task Force. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback